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ZebraﬁshThe transcription factor Sox2 is a core component of the pluripotency control circuits in the early embryo,
and later controls many aspects of neural development. Here, we demonstrate that Sox2 expression in the
epiblast (mouse blastoderm) and anterior neural plate (ANP) is determined by the upstream enhancer N2.
The mouse enhancer N2 exhibits strong activity in mouse ES cells, epiblast and ANP, and is regulated
correctly in chicken and zebraﬁsh embryos. Targeted deletion of this enhancer in mouse embryos caused a
large reduction of Sox2 expression to 10% of that of wild-type levels in epiblast and ANP. However, this was
tolerated by mouse embryo, probably due to functional compensation by Sox3. The activity of enhancer N2
depends on phylogenetically conserved bipartite POU factor-binding motifs in a 73-bp core sequence that
function synergistically, but this activation does not involve Sox2. The major POU factor expressed at the
epiblastic stage is Pou5f1 (Oct3/4), while those in the anterior neural plate are Pou3f factors (Oct6, Brn2
etc.). These factors are gradually exchanged during the transition from epiblast to ANP stages in mouse
embryos and epiblast stem cells (EpiSC). Consistently, enhancer N2 activity changes from full Pou5f1
dependence to Pou3f dependence during the development of neural plate cells (NPC) from EpiSC, as
assessed by speciﬁc POU factor knockdown in these cells. Zebraﬁsh mutant embryos completely devoid of
Pou5f1 activity failed to activate enhancer N2 and to express Sox2 in the blastoderm and ANP, and these
defects were rescued by exogenous supply of pou5f1. Previously, Pou5f1–Sox2 synergism-dependent Sox2
activation through enhancer SRR2 in ES cells has been highlighted, but this mechanism is limited to ES cells
and amniotes. In contrast, the enhancer N2-mediated, POU factor-dependent activation of Sox2, without
involvement of Sox2, is a phylogenetically conserved core mechanism that functions in gene regulatory
networks at early embryonic stages.oh).
arch Center, 2-12-1 Fukuura,
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
During early stages of embryonic development, one of the ﬁrst
major somatic tissues to develop is the neural plate, and in amniotes
this tissue is derived from the epiblast. The HMG-box transcription
factor Sox2 is regarded as a major regulator of these early
developmental stages. It is essential for post-implantation embryo-
genesis of the mouse and for ES cells (Avilion et al., 2003; Masui et al.,
2007). Sox2 expression hallmarks the neural primordia from
gastrulation stages (Rex et al., 1997; Uchikawa et al., 2003; Wood
and Episkopou, 1999) to later neural stem cells (Bylund et al., 2003;
Graham et al., 2003; Tanaka et al., 2004).The Sox2gene is continuously expressed fromearly stage blastoderm
to neural primordia of various developmental stages. This Sox2
expression is regulated by many different enhancers that have distinct
spatial speciﬁcities and developmental stage-dependence (Uchikawa et
al., 2003). At DNA level, these enhancers are signiﬁcantly conserved
between vertebrate species (Kamachi et al., 2009). Existence of such
diverse regulation for the single Sox2 gene indicates that distinct
transcriptional regulation and signaling systems are in action, depend-
ing on the developmental stages and embryonic domains.
It has been shown that cooperation of the transcription factors
Sox2 and Pou5f1 (Oct3/4) is crucial for maintenance of the pluripotent
ES cell state (Niwa, 2007; Silva and Smith, 2008), and also for
derivation of iPS cells from ﬁbroblasts (Takahashi and Yamanaka,
2006), which are largely mediated by the Pou5f1–Sox2 complex
(Kondoh and Kamachi, 2010). The enhancer SRR2 of Sox2 (Tomioka et
al., 2002) is in fact a paradigm regulatory element of Pou5f1–Sox2
synergistic target gene activation.
355M. Iwafuchi-Doi et al. / Developmental Biology 352 (2011) 354–366When gastrulation stages of mouse and chicken embryos are
analyzed, Sox2 expression in the neural plate is solely activated by
enhancers N2 and N1, which are activated in the anterior and
posterior domains, respectively, of the forming neural primordium
(Kamachi et al., 2009; Uchikawa et al., 2003). An earlier study
indicated that enhancer N1 is activated in the caudal lateral epiblast
by the synergistic action of FGF and Wnt signals (Takemoto et al.,
2006).
Here, we report enhancer N2-dependent Sox2 regulation in ES
cells, epiblast and ANP, which is a process distinct from those
dependent on N1 or SRR2. Analysis of N2 regulation using enhancer
N2 knockout embryos and mutant versions of the enhancer
demonstrated that POU factors directly activate Sox2 via enhancer
N2, interacting with the phylogenetically conserved DNA motifs in
the core region that does not contain canonical Pou5f1–Sox2
complex binding sites. Gene expression patterns, as well as the
effects of knockdown of speciﬁc POU factors, indicate that the major
functional POU factor controlling N2 is gradually shifting from
Pou5f1 to Pou3fs during the developmental progression from
epiblast to anterior neural plate. In zebraﬁsh, Pou5f1 is the only
major POU factor expressed during gastrulation (http://zf-espresso.
tuebingen.mpg.de) (Onichtchouk et al., 2010). MZspg zebraﬁsh
mutant embryos completely lacking Pou5f1 activity (Lunde et al.,
2004; Reim et al., 2004) failed to activate the enhancer N2 and
showed a precipitous reduction of Sox2 expression in the blasto-
derm and ANP, demonstrating the signiﬁcance of this regulatory
pathway.
The results of our present study reveal a new regulatory
mechanism, in which POU factors without the involvement of Sox2
directly activate Sox2 via the enhancer N2, which is signiﬁcantly
different from the regulation of the enhancer SRR2 (Tomioka et al.,
2002). This Sox2-independent regulation of enhancer N2 is widely
conserved among vertebrate species from ﬁsh to mammals, in
contrast to SRR2 that is found only among amniote species. Moreover,
the enhancer N2-dependent regulation is essential for Sox2 expres-
sion in the post-implantation stages in the mouse embryo. This is
again in contrast to SRR2, for which the regulatory activity is limited
to ES cells and possibly pre-implantation embryos. Hence, the
regulation of Sox2 by enhancer N2, as a direct target of POU factors,
represents a fundamental pathway in the gene regulatory networks
that function in early stage embryos.Materials and methods
Enhancer N2 transgenic and knockout mouse embryos
A tetrameric mouse N2 enhancer sequence inserted in the hsp68
promoter-LacZ cassette (Sasaki and Hogan, 1996) was used to
produce primary transgenic mouse embryos (Yoshimoto et al.,
2005). The targeting vector for the enhancer N2 knockout was
constructed using a 12.4 kb mouse DNA fragment containing the
enhancer N2 and Sox2 ORFs derived from BAC clone RP23-274P9
(BACPAC Resource Center, Children's Hospital Oakland Research
Institute, Oakland, CA). An FRT-ﬂanked STneoB cassette (Katoh et al.,
1987) was inserted 5′ of enhancer N2 and these were ﬂanked by LoxP
sequences. A DT-A cassette (Yagi et al., 1993) was inserted at the 5’
terminus of the vector. Linearized vector was then electroporated into
R1 ES cells (Nagy et al., 1993), and recombinants were characterized
by Southern hybridization. Heterozygous mice generated after germ-
line transmission were crossed with CAGGS-Cre mice (Sakai and
Miyazaki, 1997) to obtain the N2-deleted allele of Sox2. Embryos were
staged by morphological criteria (Downs and Davies, 1993). All
experiments involving recombinant organisms and experimental
animals were performed according to the institutional guidelines of
the authors’ afﬁliations.Immunoﬂuorescent staining of embryos
Embryos were ﬁxed in 4% paraformaldehyde in PBS at 4 °C, reacted
with goat polyclonal antibodies [anti-Sox2 (AF2018, R&D); anti-Oct3/4
(sc-8628, Santa Cruz); anti-Oct6 (sc-11661, Santa Cruz)] in TBST
(150mMNaCl, 100 mMTris–HCl [pH7.5], 0.1% Triton-X100), incubated
with AlexaFluor-488-conjugated anti-goat IgG (Invitrogen), and ob-
served using Axioplan 2 and LSM5 Pascal laser microscopes (Zeiss).
Quantitative RT-PCR analysis of mouse embryos, ES cells, EpiSC and
EpiSC-derived neural plate cells (NPC)
An egg cylinder at E7.25 derived from an N2+/­ heterozygous
cross was separated into the embryonic portion distal to the chorion
and an extra-embryonic portion. The former was processed for RNA
analysis and the latter for genotyping. RNAs were extracted using Tri
Reagent (MRC), treated with TURBO DNA-Free Kit (Ambion), and
reverse-transcribed using SuperScript III (Invitrogen). cDNAs were
quantiﬁed using the primers indicated in Table S1 and SYBR Premix
ExTaq (Takara) with PCR cycles of 5 s at 95 °C and 30 s at 60 °C in
StepOnePlus Real time PCR system (Applied Biosystems). The data
were calibrated using plasmid-cloned cDNAs, and expressed as the
relativemolecular abundance comparedwith Gapdh cDNA. RNAs from
ES cells and EpiSC were also processed accordingly.
Chicken embryos
Electroporation and whole mount in situ hybridization analyses of
chicken embryos were performed as described previously (Uchikawa,
2008; Uchikawa et al., 1999, 2003).
Zebraﬁsh embryos
Microinjection (Westerﬁeld, 1994) and whole mount in situ
hybridization of zebraﬁsh embryos (Hauptmann and Gerster, 2000)
were performed as described. Zebraﬁsh enhancer N2 activity was
examined by injecting zfN2-luciferase [zebraﬁsh N2 (541 bp; chro-
mosome:ZFISH7:22:357.257445:357.257985) in pGL4.26 (Promega)]
and CMV-Renilla luciferase vector pGL4.75 (5 pg) with or without
pou5f1 mRNA. Luciferase activities at shield stage were determined
using the dual luciferase system (Promega). qPCR analysis was
performed as described previously (Onichtchouk et al., 2010). To
generate the pCS2+pou5f1-FLAG construct, a 3×FLAG-TAG sequence
was ampliﬁed from p3xFLAG-CMV-7-vector (Sigma-Aldrich, Catalog#
E7408) and added to 3′ end of pou5f1 by fusion PCR. This fragment
was subcloned into the PCRII-Topo vector (Invitrogen), from which
the EcoRI/XhoI fragment was cloned into pCS2+.
ChIP analysis
Approximately 1000 embryos were injected with 22 ng/μl Pou5f1-
FLAG RNA or left uninjected. Embryos were homogenized at the shield
stage, andﬁxedwith 1% formaldehyde at room temperature for 10 min,
which was terminated by the addition of 0.125 M glycine. The ﬁxed
homogenatewas then incubated in cell lysis buffer (10 mMTris–HCl pH
7.5, 10 mMNaCl, 0.5% NP-40) for 5 min on ice, and nuclei werewashed
twice with PBST at 4 °C, frozen in liquid nitrogen and stored at ­80 °C
until use. A total of 2×107 nuclei of a specimen were lysed in 50 mM
Tris–HCl pH 7.5, 10 mMEDTA, 1% SDS for 10 min on ice. Chromatinwas
fragmented by sonication to an average size of 200 bp. Cell debris was
removed by centrifugation, and the supernatant diluted 1:10with ChIP
dilution buffer (16.7 mMTris–HCl pH 7.5, 167 mMNaCl, 1.2 mMEDTA,
0.01%SDS) and treated with 21 μg anti-Flag antibody (Sigma-Aldrich,
F1804) overnight at 4 °C. The chromatin–antibody complex was
collected using Dynabeads Protein G (Invitrogen, 100.04D). Chromatin
was eluted from the beads by treatmentwith 1% SDS, 0.1 MNaHCO3 for
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were reversed by treatment at 65 °C for 6 h. Following the digestion of
RNA and proteins by treatment with RNase A and proteinase K, DNA
was puriﬁed by chloroform:phenol:isoamyl alcohol extraction and
ethanol precipitation. The relative amount of Sox2 enhancer N2 region
and a rpl5b control region in the immunoprecipitated chromatin and
input control were measured by qPCR using the primers listed in Table
S2 and SYBR green mix (Thermo Scientiﬁc) in accordance with the
manufacturer's instructions in an Eppendorf Realplex light cycler. The
enrichment of N2 and rpl5b DNA sequence was estimated using the
ddCT method.
Transfection of ES cells, EpiSC, and NPC
R1 ES cells (1.5×106 in a 3.5 cm diameter dish) under a feeder-free
condition in a medium containing LIF were transfected with a mixture
of 3 μg ptk-EGFP vector DNA (Uchikawa et al., 2003) carrying the
enhancer sequence to be tested and 0.05 μg pCAGGS-mRFP1 DNA
using Lipofectamine 2000 (Invitrogen). After 24 h, ﬂuorescence was
image-recorded using an SZX12 microscope with DP50 CCD camera
(Olympus). EpiSC (Tesar et al., 2007) were dissociated using Acutase
(Sigma) and plated at a density of 1.5×105 (EpiSC) or 3×105 (NPC)
per well of a 4-well dish (#176740, Nunc), under conditions of either
EpiSC maintenance [on ﬁbronectin-coated surface and in N2B27
medium with 20 ng/ml activin (PEPROTECH) and 10 ng/ml FGF2
(PEPROTECH)] or NPC development [on gelatin-coated surface and in
N2B27 only], and added with Luciferase vector/shRNA vector DNA-
Lipofectamine mixture. Luciferase vectors were constructed by
inserting the enhancer sequences in the pδ51LucIIGL4, in which the
promoter sequence of pδ51LucII (Kamachi and Kondoh, 1993) was
inserted into pGL4.10. Luciferase activity was measured 24 h after
transfection as described above. shRNA vectors were constructed on
pSilencerU6puro (Ambion) by inserting the shRNA sequences shown
in Table S3 at the ApaI-EcoRI sites.
EMSA analysis
Recombinant Pou5f1 (82–352 a.a.), Pou3f1 (198–449 a.a.), Pou3f2
(215–445 a.a.) and Sox2 (3–206 a.a.)were synthesized via a TNT system
(Promega) using mouse cDNAs inserted into pCITE-3 (Novagen) as
templates. Probe A (12–41 bp of the N2 core sequence) and probe B
(44–73 bpof theN2 core sequence)were prepared using thepUC19BEX
vector, and EMSA analysis performed as described previously (Kamachi
and Kondoh, 1993). Sequence-speciﬁc competitors were used at
100-fold molar excess. Poly[dI-dC] or Poly[dG-dC] (to detect Sox2–
DNA interaction) at 0.1 μg/μl was used as non-speciﬁc competitor.
Results
Phylogenetically conserved activity of enhancer N2 in the ANP
Enhancer N2 was ﬁrst deﬁned as the enhancer showing activity in
the entire ANP in chicken embryos (Uchikawa et al., 2003). The
sequence of enhancer N2 is highly conserved within a 530–540 bp
region between chicken and mammals (87–90% identity) (Uchikawa
et al., 2003), and the activity of mouse enhancer N2 in electroporated
chicken embryo was found to be identical to chicken N2 (Fig. S1A).
The regulatory activity of enhancer N2 is also conserved in zebraﬁsh,
as a tkVenus reporter gene carrying mouse N2 and injected in
zebraﬁsh fertilized eggs was expressed speciﬁcally in the ANPmarked
by Sox2 expression (Fig. S1B).
In transgenicmouse embryos, mouse enhancer N2 showed activity
in the entire epiblast at E6.5, and ANP area at E7.75, as indicated by the
expression of the N2-hspLacZ transgene, coincident with Sox2
expression in the epiblast and forming ANP (Fig. 1A). This enhancer
N2 activity continued into the later forebrain (Kamachi et al., 2009).Impact of the targeted deletion of enhancer N2 upon Sox2 expression in
the epiblast/ANP
To determine the contribution of enhancer N2 to Sox2 expression in
the epiblast andANP, 538-bp sequence of this enhancerwas deleted from
the mouse Sox2 locus using ES-based targeting technology (Fig. 1B).
By crossing heterozygous (N2+/­) pairs, embryos of homozygous,
heterozygous and wild-type mice in terms of enhancer N2 ablation
were obtained in a Mendelian ratio. Expression of Sox2 in the epiblast
and ANP region, as detected by in situ hybridization, was greatly
reduced during stages E6.75 to E7.75 in N2­/­ homozygous embryos
(Fig. 1C(a)), while Sox2 expression in the extra-embryonic region
marking the periphery of chorion (asterisks in Fig. 1C(a)) was
unaffected. At E7.75, Sox2 expression in the posterior half of the
embryo initiated even in N2­/­ embryos as expected from the
contribution of other enhancers. These observations clearly indicate
that Sox2 expression in the epiblast and ANP is primarily dependent
on enhancer N2 from E6.75 to E 7.75.
Whole-mount immunostaining revealed residual Sox2 expression
in N2­/­ embryos at E7.25 (Fig. 1C(b)). Quantiﬁcation of the Sox2
mRNA levels in the embryonic portion of the egg cylinder distal to the
chorion at E7.25 by quantitative (q)RT-PCR indicated that N2­/­
embryos had only 10% of wild-type level of Sox2 (Fig. 1E), consistent
with the Sox2 immunostaining data. The residual Sox2 expression in
N2­/­ embryosmay be accounted for by (i) the very low yet detectable
activity of enhancer SRR2 in epiblast stem cells to be indicated below,
and (ii) the presence of an intact Sox2 promoter, which is known to
have some regulatory functions (Wiebe et al., 2000).
Despite this signiﬁcant reduction of Sox2 expression in the epiblast
and ANP of N2­/­ embryos, embryonic development proceededwithout
morphological abnormalities (Fig. 1C(a)). qRT-PCR analysis (Fig. 1E)
also indicated that Sox3, another group B1 Sox, is expressed at a level
comparable to Sox2 at E7.25. Assuming that the relative abundance of
mRNAs is also reﬂected by protein expression, the expression level of
Sox2 plus Sox3 in N2­/­ embryos decreased only to about two thirds of
wild-type levels (Fig. 1E). In situ hybridization analysis indicated that
Sox3 is expressed in the epiblast and ANP in a similar manner to Sox2 in
both wild-type and N2­/­ embryos (Fig. 1D). Thus, it is possible that the
reduction of Sox2 expression in the epiblast andANP inN2­/­ embryos is
functionally compensated for by the activity of Sox3.
In N2­/­ embryos Sox2 expression was gradually initiated in the
anterior CNS at around E8.5 and reached thewild-type pattern by E10.5
(Fig. S2A), possibly owing to enhancers other than N2 that commence
their activity after E8. Enhancer N2-defective homozygous pups were
born, and adult homozygous animals were normal and fertile.
To test thepossible participationof enhancerN2 in Sox2 regulation at
pre-implantation stages, we investigated Sox2 expression by immu-
nostaining using Pou5f1 expression as a reference in the blastocyst, the
stage up towhich thematernal Sox2 is carriedover (Avilion et al., 2003),
and another enhancer SRR2 possibly exhibits an activity (Tomioka et al.,
2002). We reproducibly observed a reduction of Sox2 in the inner cell
mass of N2­/­ embryos (Fig. S2B), strongly suggesting that enhancer N2
contributes to Sox2 expression at the pre-implantation stages also.
Determination of the minimal and essential core region of enhancer N2
and functional regulatory elements
As indicated above, the full-length enhancer N2 sequence is highly
conserved among amniote species (Uchikawa et al., 2003). Further
comparison of mouse N2 sequence with the corresponding genomic
regions of Xenopus identiﬁed a highly conserved 176-bp sequence
(Fig. 2A and B, and Fig. S3A). This sequence was sufﬁcient to
recapitulate the strength and ANP speciﬁcity of full-length enhancer
N2 in electroporated chicken embryos (Fig. 2C(a)). Analysis of several
overlapping subfragments in the 176-bp sequence determined the
minimal region for enhancer activity, i.e. a 73-bp N2 core, required for
Fig. 1. Enhancer N2 activity and the consequence of enhancer N2 targeted deletion in early stage mouse embryos. A. Expression of Sox2 (a) in comparison with enhancer N2-LacZ
activity (b). Enhancer N2 is active in the epiblast (ep) at E6.5, ANP (an) at E7.75 and future brain at E8.5. Bars, 200 μm. B. Strategy for deleting enhancer N2. Top: the normal allele at
the Sox2 locus. The thick lines indicate DNA sequences included in the targeting vector. Middle: the recombinant allele in which enhancer N2 plus the Neo gene are ﬂanked by LoxP
sequences (triangles). Bottom: an Enhancer N2-deleted allele produced by Cre recombinase. C. The impact of enhancer N2 targeted deletion on Sox2 expression determined by in situ
hybridization. (a) The loss of Sox2 expression in the epiblast (ep) and ANP (an) in homozygous (N2­/­) N2 knockout mouse embryos at stages E6.75, E7.5 and E7.75 compared with
wild-type embryos (N2+/+). Sox2 expression in the chorion is marked by asterisks, and that in the posterior half of the embryo by broken lines. (b) Immunoﬂuorescent staining of
E7.25 embryos for Sox2, showing residual expression in N2­/­ embryos. Bars, 200 μm. D. Comparison of Sox3 expression in wild-type and stage-matched enhancer N2 knockout
embryos at E6.75 and E7.75 by in situ hybridization. Bars, 200 μm. E. qRT-PCR analysis of Sox2 and Sox3 in the embryonic portion of late egg cylinders at E7.25, comparing wild-type
(N2+/+) and enhancer N2 knockout (N2­/­) embryos. Data for an average of 4 embryos of each genotype is shown with standard errors.
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Fig. 2. Determination of the minimal and essential core sequence of enhancer N2. A. Comparison of the mouse Sox2 locus sequence with that of chicken, Xenopus and zebraﬁsh using
VISTA plots (http://genome.lbl.gov/vista/index.shtml, 100 bp scan window). In addition to N2, enhancers located in the same region, SRR2 (Tomioka et al., 2002) and NOP-2
(Uchikawa et al., 2003), are also indicated. B. Subfragments of mouse enhancer N2[538-bp]. The N2[176-bp] sequence is strongly conserved from mouse to Xenopus. Subfragments
indicated in green displayed activity that is analogous to the full-length enhancer N2, whereas subfragments highlighted in gray showed no enhancer activity. C. Enhancer activity of
various subfragments of moue enhancer N2. (a) In electroporated chicken embryo at stage 5, as assessed by EGFP expression in ANP, in comparison with co-electroporated
N2[538-bp]-tkmRFP1. (b) In transfected ES cells, in comparison with co-transfected pCAGGS-mRFP1. Bar, 2 mm.
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sequence strongly conserved from zebraﬁsh to mouse (Fig. S3A).
Although the activity of N2 core alone was weaker than enhancer N2,
its dimeric form restored activity equivalent to the full-length
enhancer. As removal of the core sequence from the full-length 538-
bp N2 sequence eliminated enhancer activity (Fig. 2C(a)), the basic
activity of enhancer N2 is derived from the 73-bp core sequence.
When the same set of enhancer N2 fragment-bearing tkEGFP
vectors was transfected into ES cells (Fig. 2C(b)), full-length N2, 176-
bp sequence, and the N2 core dimer showed equally strong enhancer
activity, whereas the activity was lost by deletion of the core
sequence. This indicated that the same core sequence is involved in
enhancer N2 activation in the ANP, and ES cells.
POU factor-binding motif-dependent activation of enhancer N2
The enhancer N2 core sequence itself is strongly conserved across
a wide range of vertebrate species (Fig. S3A), but some speciﬁc
stretches show nearly perfect conservation (Fig. 3A). In these
sequence stretches, three sequences highly related to the octamer
motif ATGCAAAT (Verrijzer et al., 1992) were identiﬁed: POU-1
(ATTTCCAT; one-base deviation in reverse orientation), POU-2
(ATGCAGAT; one-base deviation) and POU-3 (ACTCAAAT; two-base
deviation). The latter two overlap within the composite sequence
ACTCAAATGCAGAT.
To investigate the functional signiﬁcance of these bipartite POU
factor-binding motifs, the POU-1 site and POU-2/3 composite sites
were mutated individually or in combination in the 176-bp enhancer
sequence, and the activity of mutated sequences was assessed in the
ANP of electroporated chicken embryos, and in transfected ES cells
(Fig. 3B). The effect of the POU site mutations was equivalent among
these tissue types: Mutation in either one of the POU site sequences
attenuated enhancer activity, as reﬂected by tkEGFP activation, and
this effect was similar using the double mutant of POU-1 and POU-2/3
sites. These results indicate that the POU-1 and POU-2/3 sites act
synergistically rather than additively in the activation of enhancer N2
in mouse ES cells and chicken ANP.
Enhancer N2 showed activity in the epiblast and ANP of the egg
cylinder stage mouse embryo (Fig. 1A). We investigated the effect of
POU factor site mutations on the N2 activity in these tissues, using
epiblast stem cells (EpiSC). EpiSC were derived from the epiblast and
maintained in the presence of activin, and after removal of activin
signaling differentiate into neural primordial cells that correspond to
the neural plate cells (NPC) (Brons et al., 2007; Tesar et al., 2007). As
tkEGFP exhibited a high background expression in EpiSC and EpiSC-
derived cells, a luciferase assay was employed. In transfected cultures,
enhancer N2was strongly activated in both EpiSC and NPC conditions,
but the enhancer activity was precipitously decreased by any of the
Mut-POU1, Mut-POU2/3 or Mut-POU1 plus Mut-POU2/3 double
mutations (Fig. 3B(c)). These observations indicated that simulta-
neous binding of POU factors to the core sequence is essential for
eliciting enhancer N2 activity in all examined developmental stages of
the mouse embryos.
This POU factor-dependent regulation of enhancer N2 is also
conserved in zebraﬁsh. When mouse enhancer N2[176-bp]-tkVenus/
tkmCherry vectors were injected into fertilized zebraﬁsh eggs, wild-
type enhancer strongly activated the reporter gene expression in the
ANP, while the mutant enhancer with a disruption of both POU-
binding motifs (Mut-POU1 plus Mut-POU2/3 double mutant) was
totally inactive (Fig. S4).
POU factors expressed in epiblast-ANP stages and their interaction with
the enhancer N2 core sequence
Quantitative RT-PCR analysis indicated that in ES cells and EpiSC,
Pou5f1 (Oct3/4) and Pou3f1 (Oct6) are expressed at high levels, whereasexpression other Pou3f genes, Pou3f2 (Brn2), Pou3f3 (Brn1) or Pou3f4
(Brn4) is not detectable (Fig. 4A). These data are consistent with
previous EMSA results of ES cell nuclear extract, which indicated that in
ES cells both Pou5f1 and Pou3f1 proteins are expressed abundantly
(Meijer et al., 1990). However, when the EpiSC were cultured under
conditions promoting the development of the Pou5f1 expression level
steeply decreased to one-fourth its initial level within a day, and was
totally attenuated after 48 h. During this transition period, Pou3f1
expression level decreased to half, while expression of other Pou3f
genes, Pou3f2, Pou3f3 and Pou3f4,was initiated and, and Pou3fs became
the major POU factor in NPC (Fig. 4A). The transcript levels in the
embryonic portion of E7.25 egg cylinder indicated by qRT-PCR were
comparable to those found in 24 h NPC (Fig. 4A, legend).
To determine the tissue distribution of these POU factors in the
embryos, E6.75 andE7.5 embryoswere stained for immunoﬂuorescence
using speciﬁc antibodies (Fig. 4B). At E6.75, both Pou5f1 and Pou3f1
were expressed rather uniformly in the epiblast. However, at E7.5, after
the formation of ANP, Pou5f1 expression was strongly decreased in the
ANP, whereas Pou3f1 expression was higher in the ANP than in other
regions (Fig. 4B). Pou3f2, to be expressed after E8 (Schonemann et al.,
1995; Zwart et al., 1996), was not detectable at this stage (data not
shown). These observations indicate that the sequence of events that
occurred in the EpiSC-derived cells largely recapitulates that in
developing embryos, namely that in the ES cells and epiblast, enhancer
N2 is regulated primarily by Pou5f1, whereas the regulation is gradually
taken over by Pou3f factors as ANP develops.
To conﬁrm this exchange of acting POU factors during the
formation of the ANP, we compared the effect of knockdown of
these POU factors on the activation of enhancer N2 in the epiblastic
and neural plate states of EpiSC (Fig. 4C(a)). shRNA-based knockdown
vectors with respective speciﬁcity to Pou5f1, Pou3f1 and Pou3f2 have
been constructed. Expression of the shRNAs reduced the target mRNA
levels to roughly 30% compared to control shRNA, as measured at two
developmental stages (Fig. 4C(b)). In the epiblast state cells,
knockdown of Pou5f1 signiﬁcantly reduced enhancer N2 activity,
whereas knockdown of Pou3f1 had no signiﬁcant effect on the
enhancer activity. The shRNA targeted to Pou3f2, which is not
expressed at the epiblastic stage, did not affect the N2 activity, as
expected. During the early phase of neural plate development starting
from EpiSC (24–48 h after removal of activin), however, the
knockdown of Pou5f1 became less effective, and in turn the
knockdown of Pou3f1 or Pou3f2 began to affect the enhancer activity.
At a later period (36–60 h after removal of activin) when Pou5f1
expression had ceased, Pou5f1 knockdown had no effect on enhancer
N2 activity, whereas the knockdown effect of Pou3f1 and Pou3f2 genes
persisted (Fig. 4C(a)). The limited reduction of enhancer N2 activity
by Pou3f1 or Pou3f2 knockdown is accounted for by the expression of
multiple Pou3f factors in the NPC (Fig. 4A). These results support the
model that the main POU factor that activates enhancer N2 is
gradually shifted from Pou5f1 to Pou3fs when ANP is formed.
The interaction of the POU factors with the enhancer N2 core
sequencewas analyzed using EMSA. Twoprobes A andB, corresponding
to regions 12–41 and 45–73, respectively, of the N2 core sequencewere
used in the assay (Fig. 5A), and recombinant proteins representing the
DNA-binding domains (POU-speciﬁc domain and homeodomain) of
Pou5f1, Pou3f1 and Pou3f2 were examined (Fig. 5B). Binding site
speciﬁcity was examined using non-radioactive competitors harboring
mutations in the POU site sequences (Fig. 5A).
Both probe A and probe B were bound by all POU factors (Fig. 5C),
and this binding was competed by the same unlabeled probe sequence
or a Nestin enhancer fragment harboring an octamer sequence (Tanaka
et al., 2004), but not by competitorswithmutatedPOU-1 site ormutated
POU-2/POU-3 composite site (Fig. 5D), conﬁrming that the POU factors
bind to the octamer-related sequences. Judging fromthe electrophoretic
mobility of the protein-probe complex, probe B was bound by a single
molecule of POU, at the composite POU-2 and POU-3 sites.
Fig. 3. Effects of POU site mutations in the core sequence on N2[176-bp] enhancer activity, and comparison with enhancer SRR2. A. N2 core sequence of the mouse in comparison
with that of chicken and zebraﬁsh, showing the conservation of potential POU factor-binding sequences. The mutations used in the analysis are also indicated. B. Effects of POU site
mutations in the 176-bp N2 enhancer sequence on the enhancer activity. Enhancer SRR2 [378-bp] of themouse was included in the analysis for comparison. (a)Mutation-bearing N2
[176-bp]-tkEGFP were co-electroporated with the reference vector N2[176-bp]-tkmRFP1 into stage 4 embryos and enhancer activity assessed after 4 h at stage 5. Bar, 1 mm.
(b) Effects of themutations in transfected ES cells, as indicated by the activity of N2-tkEGFP. The panels on the bottom indicate ﬂuorescence from co-transfected pCAGGS-mRFP1. Bar,
1 mm. (c) Effects of the mutations on luciferase gene activation in EpiSC and EpiSC-derived neural plate cells (NPC). Averages of four independent transfections with standard errors.
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not bind to the probe under the condition where Sox2 binds strongly
to known binding sites, exempliﬁed by enhancer N3 core sequence
(Inoue et al., 2007) (Fig. 5C). Therefore, the scenario of Sox2 activation
by cooperative action of Sox2 and POU factor proposed for theregulation in ES cells (at least through enhancer SRR2) (Niwa, 2007;
Tomioka et al., 2002) does not hold for the activation of enhancer N2.
Overall, these EMSA data in conjunction with the enhancer activity
analyses shown in Fig. 3 indicate that the simultaneous binding of
POU factors to POU-1 and POU-2/3 sites is required for the activation
Fig. 4. Changes in the POU factors involved in the activation of enhancer N2 during the developmental progression from epiblast to anterior neural plate (ANP). A. qRT-PCR analysis of
POU factor mRNA levels in ES cells, EpiSC, and EpiSC-derived neural plate cells (NPC) after 24 and 48 h in activin-free culture condition. qRT-PCR analysis of the embryonic portion of
E7.25 egg cylinders indicated the values 9.35, 5.28 and 0.10 for Pou5f1, Pou3f1 and Pou3f2, respectively. B. Immunoﬂuorescent detection of Pou5f1 and Pou3f1 in embryos at E6.75
and E7.5. Note the homogeneous distribution of Pou5f1 and Pou3f1 in the epiblast (ep) at E6.75, which is contrasted by reduction of Pou5f1 and enrichment of Pou3f1 in ANP at E7.5.
Bars, 100 μm. C. Enhancer N2 activation depends on speciﬁc POU factors in EpiSC and EpiSC-derived NPC, as assessed by the differential effects of shRNA-mediated knockdown.
(a) N2-luciferase reporter and shRNA vectors were transfected to EpiSC or EpiSC-derived NPC during the period in activin-free medium, and reporter luciferase expression was
compared with that using control shRNA. (b) The knockdown effect of shRNAs as assessed by qRT-PCR analysis using transfected EpiSC, indicated by (E) and NPC of 24–48 h in
activin-free medium, indicated by (N). Transfected cell were selected using puromycin resistance for qRT-PCR analysis.
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Fig. 5. Speciﬁc interaction of POU factors with N2 core sequence as demonstrated by EMSA. A. Probes and mutated competitor sequences used in the EMSA assay. B. Recombinant
POU factors and Sox2 used in the EMSA assay. Shaded domains of the protein were synthesized in vitro. POU, POU-speciﬁc domain; HOM, homeodomain; HMG, HMG domain.
C. Binding of recombinant factors to radio-labeled probes A and B. Note that Sox2 does not bind to probe B. Poly[dI-dC] was used with probe A, whereas poly[dG-dC] was used with
probe B and N3 core probe (Inoue et al., 2007), as the former inhibits Sox2 binding. D. Competitive inhibition of recombinant transcription factor binding to radio-labeled probes by
POU factor-binding sequences. The Nes30 competitor has a POU factor-binding site (Tanaka et al., 2004). poly[dI-dC] was used.
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binding afﬁnity of these DNA sites to the POU factors appeared
comparable, as judged from the amount of bound probe when using
Pou5f1, Pou3f1 or Pou3f2 (Fig. 5C).Pou5f1-dependent Sox2 regulation in zebraﬁsh blastoderm and ANP
Embryos lacking a speciﬁc transcription factor provide a stringent
model system to test the transcriptional regulation that involves this
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zygotic) spgmutant embryos, which are completely devoid of Pou5f1
activity (Lunde et al., 2004; Reim et al., 2004).
During the epiboly to bud stages of zebraﬁsh embryo, Pou5f1
encoded by the spg gene is the only POU factor expressed (http://zf-
espresso.tuebingen.mpg.de/) (Hauptmann and Gerster, 2000; Takeda
et al., 1994). Class III POU factor genes pou12 (zfBrn1; pou3f3a) and
pou47 (zfBrn2; pou3f2) are activated only after the bud stage
(Hauptmann and Gerster, 2000). Activation at a very low level of
Pou50 (zfOct6; pou3f1) occurs during late gastrulation, but even this
expression is absent in MZspg embryos (Onichtchouk et al., 2010).
In wild-type zebraﬁsh embryos, sox2 is expressed from the 30%
epiboly stage (Okuda et al., 2006), which may be considered
analogous to the egg cylinder stage in the mouse embryo, and is
then conﬁned to the antero-dorsal areas of the embryo, as indicated
by in situ hybridization (Fig. 6A(a)(b)(c)). In MZspgmutant embryos,
however, this sox2 expression was completely lost (Fig. 6A(d)(e)).
Even at the bud stage, sox2 expression in the ANP did not occur
(Fig. 6A(f)), while expression of sox2 in the more posterior domains
commenced, presumably owing to enhancers other than N2. This loss
of sox2 expression in the gastrulating embryo was conﬁrmed by qRT-
PCR analysis (Fig. 6B).Fig. 6. Pou5f1-dependent activation of sox2 in the blastoderm of zebraﬁsh embryo. A. sox2 in
epiboly (a and d; animal pole at top, dorsal at right), 75% epiboly (b and e, animal view) and
the ANP in the MZspgm793 embryos at bud stage. B. Rescue of sox2 expression in MZspgm793 em
qRT-PCR using the ddCT method. C. Activation of zebraﬁsh enhancer N2 by Pou5f1 in a luci
region. Embryos were injected with pou5f1-FLAGmRNA or left non-injected, and ChIP was pe
region sequence (N2) in injected embryos without enrichment of the control region (Rpl5bTo ascertain that the above observation reﬂects the enhancer N2-
dependent sox2 regulation, zebraﬁsh enhancer N2-bearing luciferase
reporter was injected into wild-type and MZspg mutant embryos
(Fig. 6C). Enhancer N2 was inactive in MZspg embryos (Fig. 6C(a)),
but the co-injection of pou5f1 mRNA activated enhancer N2 to wild-
type levels (Fig. 6C(b)). Finally, chromatin immunoprecipitation of
FLAG-tagged Pou5f1 expressed in wild-type embryos at the shield
stage conﬁrmed the binding of Pou5f1 to the genomic region of
enhancer N2 (Fig. 6D).
These results conﬁrm the essential requirement of POU factors for
the activation of enhancer N2.
Limitation of enhancer SRR2 activity to ES cells
As enhancer N2 was active in mouse ES cells, this activity was
compared with that of enhancer SRR2, which is located 1.5 kb
downstream of the Sox2 transcribed region (Fig. 2A) and known to
be active in ES cells (Tomioka et al., 2002). Enhancer SRR2 is also
presumed to play a major role in the Sox2-Pou5f1 co-regulatory loop
in ES cells (Niwa, 2007). An important difference from enhancer N2 is
that the SRR2 sequence is conserved only among amniotes (Fig. 2A
and Fig. S3B).situ hybridization of wild-type (a, b, and c) and MZspgm793 (d, e, and f) embryos at 30%
bud (c and f, anterior view, dorsal at top) stages. Note the absence of sox2 expression in
bryos by pou5f1mRNA injection (50 pg per embryo) at the 1-cell stage, as indicated by
ferase reporter assay. D. ChIP assay demonstrating Pou5f1 binding to the enhancer N2
rformed using anti-FLAG antibody. qPCR analysis shows enrichment of the enhancer N2
).
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mouse ES cells, they were activated to similar levels, indicating that
both are equally functional in these cells (Fig. 3B(b)). However, when
the same reporter genes were electroporated into chicken neural
plate, SRR2-tkEGFP failed to activate the EGFP reporter in contrast to
the strong activation by N2 (Fig. 3B(a)). When the SRR2-luciferase
construct was transfected into the EpiSC, SRR2 only marginally
activated the reporter in the epiblast state, and negligibly in the NPC
state (Fig. 3B(c)), consistent with the results using the chicken
embryo neural plate (Fig. 3B(a)). These results conﬁrm the previous
report that an SRR2-lacZ transgene expression was undetectable in
the epiblast or E8.5 neural plate (Miyagi et al., 2006).
These results indicate that in contrast to the case of mouse ES cells
and possibly blastocyst inner cell mass, where Sox2 is under a dual
regulation by enhancers N2 and SRR2, Sox2 expression in the epiblast
and ANP is primarily regulated by enhancer N2.
Discussion
POU factor-dependent activation of Sox2 through enhancer N2 as a core
regulatory mechanism at epiblast to anterior neural plate stages
Enhancer N2 was identiﬁed previously as the earliest activated
enhancer during neural plate development. N2 also shows regional
speciﬁcity of ANP among many Sox2 enhancers tested in electro-
porated chicken embryos (Uchikawa et al., 2003) and transgenic
mouse embryos (Kamachi et al., 2009). Analyses using mouse
embryos indicated that enhancer N2 also participates in Sox2
regulation at earlier developmental stages, including the epiblast
(Fig. 1A and C), ES cells (Fig. 2C(b)) and possibly in the blastocyst
inner cell mass (Fig. S2B). The great reduction of Sox2 expression
during the egg cylinder stages in enhancer N2-ablated mouse
embryos (Fig. 1C) demonstrated that this enhancer is in fact the
major Sox2 regulator at these developmental stages.
The core sequence of enhancer N2 was functionally deﬁned as a
73-bp region (Fig. 2B and C), containing highly conserved bipartite POU
factor-binding sites as essential regulatory elements (Fig. 3). The
requirement of these POU factor-binding sites for enhancer N2 activity
was demonstrated using embryos or embryonic cells from the mouse,
chicken and zebraﬁsh (Fig. 3 and Fig. S4). In fact, Pou5f1, the major
zebraﬁsh POU factor at early developmental stages, was found by
chromatin immunoprecipitation to bind in vivo to the enhancer N2
region in wild-type embryos (Fig. 6D). Moreover, Pou5f1-deﬁcient
MZspgmutants failed to activate enhancer N2 or to express sox2 in the
blastoderm and ANP, while these defects were rescued by the
exogenous injection of pou5f1 mRNA (Fig. 6B and C). These ﬁndings
establish that the POU factor-dependent activation of Sox2 regulation is
a core regulatory pathway in the early embryonic CNS.
The regions within the enhancer N2 sequence other than the core
sequence are dispensable for its activity (Fig. 2B), and are less well
conserved phylogenetically (Fig. S3A). Non-core regions are pre-
sumably involved in the ﬁne-tuning of enhancer activity and/or
function during later developmental stages, e.g., in the telencephalon
(Ferri et al., 2004).
In addition to the Pou factor-dependent regulation described here,
Sox2 regulation at the same early neural plate stages by Geminin and
related nuclear proteins, which interact with chromatin remodeling
factors, has been reported (Papanayotou et al., 2008). In the report,
physical association of Geminin with the enhancer N2 sequence in E7.5
mouse embryo is also indicated. It is possible that these two regulatory
mechanisms function in parallel or in cooperation at these stages.
Comparison of enhancer N2 with SRR2
It has been well documented that the stable ES cell state is
maintained by the mutual activation of Pou5f1 and Sox2, and via theactivation of the shared target gene Nanog (Chambers and Smith,
2004; Niwa, 2007; Silva and Smith, 2008). This mechanism has been
further highlighted by the report showing essential contribution of
Pou5f1 and Sox2 to the generation of iPS cells (Takahashi and
Yamanaka, 2006).
In addition to enhancer N2, enhancer “SRR2” located downstream
of the Sox2 gene and conserved only in amniotes (Fig. 2A and Fig. S3B)
is also known to be active in ES cells (Miyagi et al., 2006; Tomioka
et al., 2002). SRR2 is activated by the cooperative action of Pou5f1 and
Sox2 (Tomioka et al., 2002), and considered to be the major Sox2
regulatory element in ES cells (Niwa, 2007). However, a direct
comparison of the enhancer activities of N2 and SRR2 in this study
indicated that the two have comparable strengths in ES cells (Fig. 3B
(b)). Moreover, in the epiblast and ANP, enhancer N2 is the onlymajor
enhancer to regulate Sox2 expression (Figs. 1 and 3B). Hence, there
appears to be a change in the enhancers that participate in the
regulation of Sox2 expression, depending on the developmental stage
of mouse embryo. In the inner cell mass, both enhancers N2 and SRR2
regulate Sox2, but at the post-implantation stages, only enhancer N2
plays a major role.
Considering themorphologically normal development of enhancer
N2­/­ embryos, it is possible that around the time when enhancer
SRR2 loses its activity, Sox3 expression is activated, which compen-
sates for the loss of Sox2 expression in the N2­/­ embryo. Indeed,
enhancer N2­/­;Sox3-null embryos display a defect in ANP, as will be
reported elsewhere. This participation of Sox3 in the group B1 SOX-
dependent regulation also provides an explanation for the phenotypic
difference between Sox2-null and enhancer N2-deﬁcient embryos,
with the former dying shortly after implantation (Avilion et al., 2003).
It is possible that the development of Sox2 null embryos, somehow
sustained by maternal supply of Sox2 (Avilion et al., 2003), is arrested
before the activation of Sox3 that occurs only after implantation (Guo
et al., 2010). A time-resolved analysis of Sox2 and Sox3 regulation at
the stages following implantation will determine the validity of this
model.
Regulation of Sox2 by enhancer N2 at later stages
Prior to the deﬁnition of enhancer N2 in our previous report
(Uchikawa et al., 2003), S. Nicolis group reported that a “Sox2 5’
regulatory region (­3.3 kb to ­5.7 kb),” which includes enhancer N2
region, acts as an enhancer in the ICM, epiblast, ANP and later
forebrain (Zappone et al., 2000). Tomioka et al. (2002) have also
described an analogous region denoted “SRR1.” However, the
regulatory mechanisms that operate at the early post-implantation
stages have not been studied, namely the time window in which
enhancer N2 is essential for Sox2 activation.
Nicolis group additionally carried out analysis of this region
focusing on the telencephalic development (Catena et al., 2004), and
identiﬁed a 400 bp subdomain of the “Sox2 5’ regulatory region,”
which includes the enhancer N2 core sequence that is important for
the expression of Sox2 in the E12.5 embryonic forebrain. The same
study also showed the involvement of POU factor-binding sites, one of
which coincides with the POU-1 site in our present study (Fig. S3A).
These ﬁndings indicated some similarities in Sox2 regulation between
the ANP and the forebrain, but the reported data for transgene
expression levels and expression patterns (Catena et al., 2004)
strongly suggest that the regulation in the forebrain is more complex
than in the ANP.
Threshold levels for the requirement of group B1 Sox activity for normal
development and functional compensation among B1 SOX proteins
Enhancer N2 knockout mouse embryo displayed signiﬁcant
reduction in Sox2 expression in the epiblast and ANP, to 10% of the
wild-type level (Fig. 1C and E). Despite this reduction in Sox2, the
Fig. 7. Major regulatory pathways at the early embryonic and epiblast-ANP stages,
involving POU and B1 SOX factors. Earlier studies using ES cells have highlighted
pathway B, but this study demonstrates the importance of pathway A involving POU-
dependent yet SOX B1-independent activation of target genes.
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ities through the E6–E9 period, after which Sox2 expression appeared
to be supported by the activity of other enhancers. Thus, at the egg
cylinder stages, the requirement for Sox2 activity at ﬁrst view appears
surprisingly low, but can be explained by a high Sox3 expression level
(Fig. 1D and E), which sustains the B1 SOX activity level in the
enhancer N2 knockout egg cylinder to two-third that of wild-type.
Sharing of the same functions among B1 Sox genes is supported by
the previous observations in zebraﬁsh embryos. In zebraﬁsh, four B1
Sox genes, sox19a, sox19b, sox2 and sox3 are expressed at the
blastoderm-early neural plate stages (Okuda et al., 2006), and only
by simultaneous knockdown of all four of these genes are severe
developmental defects induced (Okuda et al., 2010).
The threshold B1 Sox expression levels to be required for normal
developmental progression appear to depend on the developmental
stages and tissues. In the developing retina of themousewhere Sox3 is
not expressed, the reduction of Sox2 expression to below 40% of wild-
type levels affected retinal histogenesis (Taranova et al., 2006). In the
adult mouse CNS, reduction of Sox2 expression to 25–35% of wild-type
caused impairment of neurogenesis associated with neurodegenera-
tion (Ferri et al., 2004).
POU factor-dependent B1 Sox activation as a phylogenetically conserved
regulatory mechanism in early embryonic development
The results of our present study demonstrated that the enhancer
N2-dependent regulation of Sox2 by POU factors at the epiblast-ANP
stages is strongly conserved across vertebrate species, from ﬁsh to
mammals. In ﬁsh, four B1 sox genes, sox19a, sox19b, sox3 and sox2, are
active in early stage embryos, as discussed above (Okuda et al., 2010,
2006). It is interesting to note in this regard that zebraﬁsh MZspg
mutant embryo, lacking a POU factor activity at early stages, failed to
activate both zygotic sox19b and sox2 expression, and decreased sox3
expression (Onichtchouk et al., 2010). Thus, POU factor-dependent
activation appears to be a general and conserved mechanism to
regulate B1 Sox genes at the epiblast/blastoderm stages and in early
embryonic CNS.
Our recent studies using zebraﬁsh have indicated remarkable
similarities in the early embryonic phenotypes of MZspg mutants
(Onichtchouk et al., 2010) and B1 sox quadruple knockdown embryos
(Okuda et al., 2010). It has been demonstrated that a subset of genes
affected in common are under synergistic regulation by Pou5f1 and B1
SOX, analogous to gene regulations taking place in ES cells (Kondoh
and Kamachi, 2010; Okuda et al., 2010; Onichtchouk et al., 2010). This
synergism between Pou5f1 and B1 SOX likely underlies the develop-
ment of common phenotypes in MZspg and quadruple B1 Sox
knockdown embryos (Fig. 7, pathway B). This present study, however,
demonstrated that a second mechanism operates in parallel, and
contributes to these phenotypic similarities, namely the direct
activation of the B1 Sox genes, as exempliﬁed by the enhancer N2
regulation of Sox2 (Fig. 7, pathway A). This new pathway is actually
predominant, and accounts for Sox2 regulation in the epiblast and
ANP in mouse embryos (Fig. 1). Further examination of the gene
regulatory networks involving POU and B1 SOX factors should
consider both these pathways, which may change their relative
contributions depending on the cell type and developmental stage.
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